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Abstract: Efficient synthesis of 5-aminosulfonyl uracil derivatives 2−9 and results of their antiproliferative activity are provided. Sulfonylation of 
the amino group in 5-aminouracil 1 with selected arylsulfonyl chlorides occurs regioselectively when the reaction is carried out in pyridine at 
room temperature. Simple isolation of the products by recrystallization of the crude product mixture from aqueous methanol provides good 
to excellent yields. The prepared 5-aminosulfonyl uracil derivatives 2−9 were tested for the antiproliferative activity on a panel of seven tumor 
cell lines of different histological origin (HeLa, Caco-2, NCI-H358, Raji, HuT78, Jurkat, K562) and normal MDCK I cells. Derivatives 2−9 were 
found more efficient to lymphoma and leukemia cells compared to solid tumor and normal cells. 
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INTRODUCTION 
HE pyrimidine derivatives are known as essential 
constituents of nucleic acids and exhibit a variety of 
biological activities[1] notable among which are the anti-
bacterial,[2–4] anticancer,[5–8] anti-inflammatory,[9,10] anti-
tubercular,[11] analgesic,[12] and antiviral[13–15] activities. The 
pyrimidine base with modification at C5 position provides 
the enhanced biological activity of the nucleobase and 
nucleoside analogs.[16–18] 
 5-Fluorouracil[19,20] and the nucleoside floxuridine[21] 
are frequently used for the treatment of various cancers. 
Uramustine[22] is used orally in the treatment of leukemia 
and thymine derivative HEPT is considered as a non-
nucleoside reverse transcriptase inhibitor in HIV-infection 
therapy (Figure 1).[23] 5-Bromouracil and 5-aminouracil 
could be incorporated into nucleic acids and could interfere 
with their transcription or translation processes. They also 
represent good starting material for the synthesis of the 
fluorescent uracil derivatives suitable for incorporation into 
PNA's or nucleic acids.[24–29] 
 Our group has a long-term experience in design, 
synthesis, and characterization of biologically active nucleo-
side derivatives.[30–33] Previously, we have synthesized  
N-sulfonylpyrimidine derivatives I (Figure 2) as a new type 
of sulfonylcycloureas.[34–37] These compounds showed 
strong antiproliferative activity on human tumor cell lines, 
in in vitro[38–41] and in vivo[42–45] conditions. 
T 
 
Figure 1. Structures of some biologically active C-5 
substituted pyrimidine derivatives. 
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The promising anticancer activity of 1-sulfonyl-
pyrimidines I inspired the design and synthesis of novel 
series of 5-aminosulfonyl uracil derivatives of general 
structure II (Figure 2; compounds 2−9, Scheme 1). 
Sulfonylation of 5-aminouracil I appears particularly 
interesting due to its enhanced hydrogen bonding ability by 
5-amino hydrogens which enables the formation of 
quadruplex and triplex structures.[46,47] By 5-amino 
sulfonylation of I its hydrogen bonding potential is retained 
and could be even enhanced due to increased acidity of 
sufonylamide hydrogen.  
 For sulfonylation of 1, the aromatic sulfonyl 
chlorides with different size and lipophilicity of aromatic 
groups with electron-donating or electron-withdrawing 
substituents on the aromatic system were selected. In this 
way, the molecules with variable electronic and lipophilic 
characteristics could be obtained, which may influence 
their chemical stability as well as physical and biological 
properties. Here we report the synthesis of 5-amino-
sulfonyl uracil derivatives 2−9 as well as their anti-
proliferative activity on normal MDCK I cells, and HeLa, 
Caco-2, NCI-H358, Raji, HuT78, Jurkat, and K562 tumor cell 
lines. 
 
EXPERIMENTAL  
General  
Chemicals and solvents were obtained from Sigma–Aldrich 
Chemical Company (St. Louis, USA) and used without 
further purification. Rf values refer to analytical TLC 
performed using pre-coated silica gel 60 F254 plates 
purchased from Sigma–Aldrich (Steinheim, Germany) and 
developed in the solvent system indicated. Compounds 
were visualized by use of UV light (254 and 365 nm). 
Melting points were determined on a Kofler hot-stage 
apparatus and were uncorrected. UV spectra were taken on 
a Philips PU8700 UV/VIS spectrophotometer (Philips 
Analytical, Cambridge, Great Britain). IR spectra were 
obtained in KBr pellets on a Perkin-Elmer 297 spectro-
photometer (Perkin-Elmer, Waltham, MA, USA). NMR 
spectra were recorded on AV600 and AV300 MHz 
spectrometers (Bruker BioSpin GmbH, Rheinstetten, 
Germany), operating at 150.92 or 75.47 MHz for 13C and 
600.13 or 300.13 MHz for 1H nuclei using DMSO-d6 as the 
internal standard. Elemental analyses were performed by 
the Applied Laboratory Research Department at INA, d.d. 
Research and Development Sector, Central Analytical 
Laboratory. 
 
General Procedure for the Condensation of 5-aminouracil 1 
with sulfonyl chlorides  
A suspension of 5-aminouracil 1 (1 mmol) in dry pyridine 
(7.5 mL) was cooled to 0 °C and the appropriate sulfonyl 
chloride (1 mmol) was added. The reaction mixture was 
stirred at room temperature until the TLC showed the 
reaction was completed (1.5−20 h). The solvent was 
removed under reduced pressure and the crude product 
was recrystallized from methanol or aqueous methanol to 
afford the product. 
 
N-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-methyl-
benzenesulfonamide (2) 
Compound 2 was made in a different way than described in 
Ref. [48]. According to the general procedure, 5-amino-
uracil 1 (0.5 g, 3.93 mmol) and tosyl chloride (0.749 g, 3.93 
mmol) in pyridine (29 mL) were reacted for 19 h. Recrystal-
lization from aqueous methanol gave the analytically pure 
product 2 as white crystals: 1.08 g (98 %; lit.[48] 49 %); Rf = 
0.55 (CH2Cl2/MeOH 9:1); m.p. >300 °C; UV (MeOH): 
λmax/nm: 218 and 272; log ε/ dm3 mol–1 cm–1: 4.10 and 3.08; 
IR (KBr) νmax/cm–1: 3330 (s), 3125 (m), 3042 (m), 2921 (w), 
1689 (s), 1647 (s), 1414 (s), 1358 (m), 1222 (s), 1169 (s), 
1092 (m); 1H NMR (DMSO-d6) δ/ppm: 11.18 (s, 1H, NH-3), 
10.88 (brs, 1H, NH-1), 9.24 (brs, 1H, NH-SO2), 7.62 (d, J = 8.2 
Hz, 2H, Ar), 7.32 (d, J = 8.2 Hz, 2H, Ar), 7.30 (brs, 1H, H-6), 
2.35 (s, 3H, CH3); 13C NMR (DMSO-d6) δ/ppm: 161.0 (C-4), 
150.3 (C-2), 142.9 (Cq, Ar), 138.6 (C-6), 137.5 (Cq, Ar), 129.3 
(CH, Ar), 126.9 (CH, Ar), 110.2 (C-5), 21.0 (CH3); (see 
Supporting Information Figures S1, S2). Anal. Calcd. mass 
fractions of elements, w/%, for C11H11N3O4S (Mr = 281.29) 
are: C, 46.97; H, 3.94; N, 14.94; S, 11.40; found: C, 47.02; H, 
3.98; N, 15.00; S, 11.47. 
 
N-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2,4,6-
triisopropylbenzenesulfonamide (3) 
According to the general procedure, 5-aminouracil 1 (0.5 g, 
3.93 mmol) and 2,4,6-triisopropylbenzenesulfonyl chloride 
(1.23 g, 3.93 mmol, 97 %) in pyridine (29 mL) were reacted 
for 12 h. Recrystallization from methanol gave the 
analytically pure product 3 as white crystals: 1.31 g (85 %); 
Rf = 0.32 (CH2Cl2/MeOH, 20:1); m.p. >300 °C (decom.); UV 
(MeOH): λmax/nm: 206, 208, and 278; log ε/ dm3 mol–1 cm–1: 
4.61, 4.61, and 3.89; IR (KBr) νmax/cm–1: 3318 (m), 3133 (m), 
2958 (m), 1721 (s), 1654 (s), 1490 (w), 1425 (m), 1248 (m), 
1144 (s), 902 (w); 1H NMR (DMSO-d6) δ/ppm: 11.17 (s, 1H, 
NH-3), 10.93 (d, 1H, J = 4.8 Hz, NH-1), 9.08 (s, 1H, NH-SO2), 
7.29 (d, 1H, J = 6.1 Hz, H-6), 7.16 (s, 2H, Ar), 4.00−3.87 (m, 
 
Figure 2. Structures of 1-sulfonylpyrimidines I and 5-amino-
sulfonyl uracil derivatives II. 
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2H, CH-Ar), 2.95−2.82 (m, 1H, CH-Ar), 1.20−1.14 (m, 18H, 
CH-CH3); 13C NMR (DMSO-d6) δ/ppm: 161.3 (C-4), 151.9 (Cq, 
Ar), 150.3 (C-2), 149.8 (Cq, Ar), 139.7 (C-6), 134.0 (Cq, Ar), 
123.3 (CH, Ar), 109.2 (C-5), 33.1 (CH-CH3), 29.5 (CH-CH3), 
24.5 (CH-CH3), 23.3 (CH-CH3); (see Supporting Information 
Figures S3, S4). Anal. Calcd. mass fractions of elements, 
w/%, for C19H27N3O4S (Mr = 393.50) are: C, 57.99; H, 6.92; 
N, 10.68; S, 8.15; found: C, 58.03; H, 6.98; N, 10.70; S, 8.17. 
 
4-Acetamido-N-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-
benzenesulfonamide (4) 
Compound 4 was prepared by modification of the 
described procedures.[49,50] According to the general 
procedure, 5-aminouracil 1 (0.5 g, 3.93 mmol) and 4-acet-
amidobenzenesulfonyl chloride (0.937 g, 3.93 mmol, 98 %) 
in pyridine (29 mL) were reacted for 20 h. Recrystallization 
from methanol gave the analytically pure product 4 as light 
brown crystals: 0.828 g (65 %): Rf = 0.22 (CH2Cl2/MeOH, 
20:1); m.p. >290 °C (decom.), (lit.[50] m.p. >285−287 °C); UV 
(MeOH): λmax/nm: 206 and 263; log ε/ dm3 mol–1 cm–1: 4.13 
and 4.08; IR (KBr) νmax/cm–1: 3446 (w), 3321 (m), 3277 (m), 
3035 (m), 2842 (m), 1735 (s), 1667 (s), 1586 (s), 1534 (s), 
1494 (m), 1396 (m), 1313 (m), 1152 (s), 1011 (w), 846 (m); 
1H NMR (300 MHz, DMSO-d6) δ/ppm: 11.17 (s, 1H, NH-3), 
10.88 (brd, 1H, J = 5.0 Hz, NH-1), 10.28 (s, 1H, NH-C=O), 9.16 
(s, 1H, NH-SO2), 7.70 (d, J = 8.9 Hz, 2H, Ar ), 7.65 (d, J = 9.0 
Hz, 2H, Ar), 7.29 (d, 1H, J = 6.1 Hz, H-6), 2.07 (s, 3H, CH3); 
13C NMR (DMSO-d6) δ/ppm: 168.9 (O=C-CH3) 161.0 (C-4), 
150.3 (C-2), 143.0 (Cq, Ar), 138.5 (C-6), 133.8 (Cq, Ar), 128.0 
(CH, Ar), 118.2 (CH, Ar), 110.1 (C-5), 24.1 (q, CH3); (see 
Supporting Information Figures S5, S6). Anal. Calcd. mass 
fractions of elements, w/%, for C12H12N4O5S (Mr = 324.31) ) 
are: C, 44.44; H, 3.73; N, 17.28; S, 9.89; found: C, 44.49; H, 
3.74; N, 17.30; S, 9.91. 
 
N-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-nitro-
benzenesulfonamide (5) 
Compound 5 was prepared by modification of the 
described procedure.[50] According to the general proced-
ure, 5-aminouracil 1 (0.5 g, 3.93 mmol) and 4-nitro-
benzenesulfonyl chloride (0.898 g, 3.93 mmol, 97 %) in 
pyridine (29 mL) were reacted for 19 h. Recrystallization 
from aqueous methanol gave the analytically pure product 
5 as a light brown solid: 0.761 g (62 %); Rf = 0.52 
(CH2Cl2/MeOH, 20:1); m.p. >300 °C (decom.), (lit.[50] m.p. 
>300 °C); UV (MeOH): λmax/nm: 202, 204, and 266 log ε/ 
dm3 mol–1 cm–1: 4.03, 4.06, and 3.99; IR (KBr) νmax/cm–1: 
3338 (s), 3113 (s), 3038 (m), 2923 (m), 1689 (s), 1648 (s), 
1541 (s), 1416 (s), 1352 (s), 1313 (m), 1221 (s), 1174 (s), 
1090 (m), 925 (m); 1H NMR (DMSO-d6) δ/ppm: 11.21 (s, 1H, 
NH-3), 11.03 (brs, 1H, NH-1), 9.77 (brs, 1H, NH-SO2), 8.36 
(d, 2H, J = 8.8 Hz, Ar), 8.01 (d, 2H, J = 8.8 Hz, Ar), 7.48 (s, 1H, 
H-6); 13C NMR (DMSO-d6) δ/ppm: 161.1 (C-4), 150.4 (C-2), 
149.6 (Cq, Ar), 146.1 (Cq, Ar), 140.5 (C-6), 128.5 (CH, Ar), 
124.2 (CH, Ar), 109.2 (C-5); (see Supporting Information 
Figures S7, S8). Anal. Calcd. mass fractions of elements, 
w/%, for C10H8N4O6S (Mr = 312.26) are: C, 38.46; H, 2.58; N, 
17.94; S, 10.27; found: C, 38.51; H, 2.59; N, 17.96; S, 10.30. 
 
N-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-nitro-
benzenesulfonamide (6)  
According to the general procedure, 5-aminouracil 1 (0.5 g, 
3.93 mmol) and 2-nitrobenzenesulfonyl chloride (0.871 g, 
3.93 mmol, 97 %) in pyridine (29 mL) were reacted for 20 h. 
Recrystallization from methanol gave the analytically pure 
product 6 as red crystals: 0.726 g (59 %); Rf = 0.22 
(CH2Cl2/MeOH, 20:1); m.p. 280 °C (decom.); UV (MeOH): 
λmax/nm: 268 and 326; log ε/ dm3 mol–1 cm–1: 3.99 and 2.92; 
IR (KBr) νmax/cm–1: 3313 (m), 3108 (m), 3027 (m), 2830 (m), 
1715 (s), 1679 (s), 1542 (s), 1421 (s), 1385 (s), 1325 (m), 
1168 (s), 910 (m); 1H NMR (DMSO-d6) δ/ppm: 11.23 (s, 1H, 
NH-3), 11.02 (brd, 1H, J = 5.4 Hz, NH-1), 9.70 (brs, 1H, NH-
SO2), 8.08−7.80 (m, 4H, Ph), 7.41 (d, 1H, J = 6.3 Hz, H-6); 13C 
NMR (DMSO-d6) δ/ppm: 161.4 (C-4), 150.5 (C-2), 147.6 (Cq, 
Ar), 140.8 (C-6), 134.3 (CH, Ar), 132.6 (Cq, Ar), 132.2 (CH, 
Ar), 130.4 (CH, Ar), 123.8 (CH, Ar), 109.2 (C-5); (see 
Supporting Information Figures S9, S10). Anal. Calcd. mass 
fractions of elements, w/%, for C10H8N4O6S (Mr = 312.26) 
are: C, 38.46; H, 2.58; N, 17.94; S, 10.27; found: C, 38.49; H, 
2.61; N, 17.99; S, 10.28. 
 
4-Cyano-N-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-
benzenesulfonamide (7) 
According to the general procedure, 5-aminouracil 1 (0.250 g, 
1.97 mmol) and 4-cyanobenzenesulfonyl chloride (0.410 g, 
1.97 mmol, 97 %) in pyridine (15 mL) were reacted for 1.5 h. 
Recrystallization from methanol gave the analytically pure 
product 7 as orange crystals: 0.403 g (70 %); Rf = 0.44 
(CH2Cl2/MeOH, 20:1); m.p. > 300 °C decom.; UV (MeOH): 
λmax/nm: 202, 231, and 271; log ε/ dm3 mol–1 cm–1: 4.03, 
3.95, and 3.76; IR (KBr) νmax/cm–1: 3341 (s), 3112 (s), 2815 
(m), 2236 (w), 1782 (w), 1690 (s), 1517 (w), 1416 (s), 1362 
(s), 1221 (s), 1172 (s), 1089 (m); 1H NMR (DMSO-d6) δ/ppm: 
11.19 (s, 1H, NH-3), 10.99 (d, 1H, J = 4.8 Hz, NH-1), 9.66 (s, 
1H, NH-SO2), 8.02 (d, 2H, J = 8.4 Hz, Ar), 7.92 (d, 2H, J = 8.4 
Hz, Ar), 7.43 (d, 1H, J = 6.2 Hz, H-6); 13C NMR (DMSO-d6) 
δ/ppm: 161.1 (C-4), 150.4 (C-2), 144.6 (Cq, Ar), 140.4 (C-6), 
133.0 (CH, Ar), 127.7 (CH, Ar), 117.8 (Cq, Ar), 114.9 (C≡N), 
109.2 (C-5); (see Supporting Information Figures S11, S12). 
Anal. Calcd. mass fractions of elements, w/%, for 
C11H8N4O4S (Mr = 292.27) are: C, 45.20; H, 2.76; N, 19.17; S, 
10.97; found C, 45.25; H, 2.80; N, 19.19; S, 11.01. 
 
N-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphtha-
lene-1-sulfonamide (8) 
According to the general procedure, 5-aminouracil 1 (0.5 g, 
3.93 mmol) and 1-naphtalenesulfonyl chloride (0.918 g, 
3.93 mmol, 97 %) in pyridine (29 mL) were reacted for 6 h. 
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Recrystallization from methanol gave the analytically pure 
product 8 as yellow crystals: 0.723 g (58 %); Rf = 0.75 
(CH2Cl2/MeOH, 20:1); m.p. 294−296 °C; UV (MeOH): 
λmax/nm: 203, 220, and 279 log ε/ dm3 mol–1 cm–1, 4.81, 
4.86, and 4.28; IR (KBr) νmax/cm–1: 3182 (m), 2923 (m), 1711 
(s), 1663 (s), 1430 (m), 1354 (m), 1226 (m), 1164 (s), 1134 
(s); 1H NMR (DMSO-d6) δ/ppm: 11.09 (s, 1H, NH-3), 10.86 
(d, 1H, J = 5 Hz, NH-1), 9.61 (s, 1H, NH-SO2), 8.69 (d, 1H, J = 
9.5 Hz, Ar), 8.21−8.04 (m, 3H, Ar), 7.71−7.56 (m, 3H, Ar), 
7.23 (d, 1H, J = 6.1 Hz, H-6); 13C NMR (DMSO-d6) δ/ppm: 
161.1 (C-4), 150.3 (C-2), 138.7 (C-6), 135.7 (Cq, Ar), 134.1 
(CH, Ar), 133.8 (Cq, Ar), 128.8 (CH, Ar), 127.9 (Cq, Ar), 127.6 
(CH, Ar), 126.7 (CH, Ar), 125.1 (CH, Ar), 124.3 (CH, Ar), 110.0 
(C-5); (see Supporting Information Figures S13, S14). Anal. 
Calcd for C14H11N3O4S (Mr = 317.32) are: C, 52.99; H, 3.49; N, 
13.24; S, 10.10; found: C, 53.04; H, 3.51; N, 13.28; S, 10.12. 
 
(E)-4-((4-(Dimethylamino)phenyl)diazenyl)-N-(2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-5-yl)benzenesulfonamide (9) 
According to the general procedure, 5-aminouracil 1 (0.098 
g, 0.77 mmol) and 4-N,N-dimethylaminoazobenzene-4'-
sulfonyl chloride (0.256 g, 0.77 mmol, 97.5 %) in pyridine  
(6 mL) were reacted for 6 h. Recrystallization from 
methanol gave the analytically pure product 9 as a brown 
solid: 0.268 g (84 %); Rf = 0.71 (CH3CH2CH2OH/NH3/H2O 
7:1:2); m.p. >300 °C; UV (MeOH): λmax/nm: 204, 272, and 
427; log ε/ dm3 mol–1 cm–1: 3.65, 3.38, and 3.62; IR (KBr) 
νmax/cm–1: 3320 (s), 3112 (s), 1691 (s), 1603 (s), 1519 (s), 
1411 (s), 1361 (s), 1233 (s), 1145 (s), 1026 (s), 838 (s), 764 
(s); 1H NMR (DMSO-d6) δ/ppm: 11.20 (s, 1H, NH-3), 10.96 
(d, 1H, J = 5.9 Hz, NH-1), 9.43 (s, 1H, NH-SO2), 7.88–7.73 (m, 
6H, Ar), 7.38 (d, J = 6.2 Hz, 1H, H-6), 6.86 (d, J = 9.1 Hz, 2H, 
Ar), 3.08 (d, J = 5.2 Hz, 6H, NCH3); 13C NMR (DMSO-d6) 
δ/ppm: 161.1 (C-4), 154.5 (Cq, Ar), 153.2 (Cq, Ar), 150.4 (C-
2), 142.6 (Cq, Ar), 140.0 (Cq, Ar), 139.3 (C-6), 128.3 (CH, Ar), 
125.6 (CH, Ar), 121.9 (CH, Ar), 111.8 (CH, Ar), 109.9 (C-5), 
39.9 (N-CH3); (see Supporting Information Figures S15, 
S16). Anal. Calcd. mass fractions of elements, w/%, for 
C18H18N6O4S (Mr = 414,44) are: C, 52.17; H, 4.38; N, 20.28; 
S, 7.74; found: C, 52.21; H, 4.40; N, 20.31; S, 7.76. 
 
Cell Culturing and MTT Test[51] 
5-Aminosulfonyl uracil derivatives 1−9 and 5-fluorouracil  
(5-FU) as the positive control, were selected for preliminary 
in vitro cytotoxicity testing against normal Madin-Darby 
canine kidney (MDCK I) cells, and seven tumor cell lines of 
different histological origin: cervix adenocarcinoma cells 
(HeLa), human epithelial colorectal adenocarcinoma cells 
(Caco-2), human caucasian bronchioalveolar carcinoma cells 
(NCI-H358), human Burkitt lymphoma cells (Raji), human T 
cell lymphoma cells (HuT78), human acute T cell leukemia 
cells (Jurkat, and chronic myelogenous leukemia cells (K562).  
 The NCI-H358, Raji, HuT78, Jurkat, and K562  
cells were grown in RPMI 1640 medium (Gibco, EU) 
supplemented with 10 % heat-inactivated fetal bovine 
serume FBS (Gibco, EU), 2 × 10–3 mol dm–3 glutamine 
(Gibco, EU), 1 × 10–3 mol dm–3 sodium pyruvate (Gibco, EU), 
1 × 10–2 mol dm–3 HEPES (Sigma-Aldrich, USA) and 100 
U/0.1 mg penicillin/streptomycin. The MDCK I, HeLa and 
Caco-2 cells were grown in Dulbecco’s Modified Eagle 
Medium DMEM (Gibco, EU), supplemented with 10 % FBS, 
2 × 10–3 mol dm–3 glutamine and 100 U/0.1 mg penicillin/ 
streptomycin; in tissue culture flasks and grown as mono-
layers. To detach them from the flask surface, cells were 
trypsinized using a 0.25 % trypsin/EDTA solution. Cells were 
cultured in a humidified atmosphere under the conditions 
of 37 °C / 5 % of CO2 gas in a CO2 incubator (Shell Lab, 
Sheldon Manufacturing, USA). 
 Tested compounds were dissolved in dimethyl 
sulfoxide as a 1 × 10–2 mol dm–3 stock solution. Working 
dilutions of derivatives 2−8 and 5FU were prepared in high 
pure water at a concentration range 10–4−10–7 mol dm–3 
and in the case of insoluble compound 9 at a concentration 
range 10–5–10–7 mol dm–3. 
 For the MTT test, the adherent cells, MDCK I, HeLa, 
and Caco-2, were seeded in 96 micro-well plates at 
concentration of 2×104 cells/cm3 and allowed to attach 
overnight in the CO2 incubator. After 72 hours of the expos-
ure to tested compounds, medium was replaced with  
5 mg/cm3 MTT solution and the resulting formazane 
crystals were dissolved in DMSO. 
 Leukemia cells (1 × 105 cells/cm3) were plated onto 
96 micro-well plates and after 72 hours of incubation,  
5 mg/cm3 MTT solution was added to each well and 
incubated 4 hours in the CO2 incubator. To each well, 10 % 
SDS with 0.01 mol dm–3 HCl was added to dissolve water-
insoluble MTT-formazane crystals. The microplate reader 
(iMark, BIO RAD, Hercules, CA, USA) was used for measure-
ment of the absorbance at 595 nm.  
 All experiments were performed three times in 
triplicates. The percentage of treated tumor cells growth 
inhibition was calculated relative to the growth of 
untreated (control) cells. 
 Selectivity index (SI) was calculated for each 
compound using formula: SI = IC50 for normal cell line  
MDCK I / IC50 for respective tumor cell line. Higher values of 
SI indicate greater antitumor specificity and the SI > 1.00 
identifies compounds with efficacy against tumor cells 
greater than toxicity against normal cells.[52–54] 
 
RESULTS AND DISCUSSION 
Synthesis 
Depending on the reaction conditions, alkylation of uracil 
with alkyl halides may result in N-1 or N-3, alkylated and  
N-1,N-3-dialkylated products. For example, in the reaction 
 
 
 
 H. ISMAILI et al.: An Efficient Synthesis and In vitro Cytostatic Activity of … 273 
 
DOI: 10.5562/cca3567 Croat. Chem. Acta 2019, 92(2), 269–277 
 
 
 
of uracil with a high excess of methyl iodide, in the presence 
of alkali, 1,3-dimethyl uracil was formed,[55] while the 
alkylation with a small excess alkyl halide in the presence of 
a base in DMF yields N-1-alkylated products with a small 
amount of N-1,N-3-dialkylated compounds.[56–57] 
 On the other hand, 5-aminouracil 1 provides greater 
substitution possibilities due to the presence of a basic 
amino group at the C5 position of the ring. When potassium 
salt of 5-aminouracil is allowed to react with methyl iodide 
alkylation takes place in the N1 and N3 positions of the 
pyrimidine ring with formation of 1,3-dimethyl-5-amino-
uracil.[48] Treatment of 5-aminouracil 1 with p-toluene-
sulfonyl chloride in aq. sodium hydroxide gave 5-amino-
tosyl uracil 2 in 49 % yield,[48] while 5-sulfanilamidouracil[49] 
was synthesized by reacting 5-aminouracil 1 and N-acetyl-
sulfanilyl chloride in pyridine, followed by deprotection of 
N-acetyl group in aqueous sodium hydroxide (52 % yield). 
Pecorari et al.[50] showed that in the reaction of  
4-acetamido and 4-nitrobenzenesulfonyl chloride with  
5-aminouracil 1 in aq. sodium hydroxide, mono C5 
aminosulfonyl products 4 and 5 are formed in a mixture 
with different amounts of disubstituted products (N5,N5-
bis-sulfonyl), depending on pH. 
 We have previously described two methods for the 
preparation of N-1-sulfonylpyrimidine derivatives of 
general formula I (Figure 2): a) condensation of silylated 
pyrimidine bases with different sulfonyl chlorides in 
acetonitrile; b) reaction of pyrimidine bases with sulfonyl 
chlorides in pyridine.[34,36] The above procedures worked 
well with aliphatic, aromatic, and heteroaromatic sulfonyl 
chlorides.  
 For the synthesis of the 5-aminosulfonyl uracil 
derivatives of general formula II (Figure 2), we used  
5-aminouracil 1 and applied the method b) in pyridine for 
the regioselective introduction of the aromatic sulfonyl 
groups to the C5 amino group of uracil ring. 
 The substitution of the amino group in 1 proceeded 
well when equimolar amounts of 5-aminouracil 1 and  
p-toluenesulfonyl chloride were reacted in pyridine at room 
temperature. After simple isolation by recrystallization of 
the crude product mixture from aqueous methanol,  
5-aminotosyl uracil 2 was isolated in 98 % yield (Scheme 1). 
 Employing the latter reaction conditions with 
commercially available arylsulfonyl chlorides, which have 
previously been associated with antitumor activity,[58–60] 
the respective 5-aminosulfonyl uracil derivatives 3−9 were 
obtained in good to excellent yields (Scheme 1).  
 The structures of the synthesized compounds were 
confirmed by elemental analysis and by IR and NMR data. 
The 1H NMR spectra of the products 2-9 confirm the 
respective structures of 5-aminosulfonyl uracil derivatives. 
Singlets, in the NMR spectra of 2-9 appearing in the range 
of δ 11.09–11.23 ppm, are attributed to the uracil N3 
protons. The uracil N1 protons appear as broad singlets (2 
and 5 at 10.88 and 11.03 ppm, respectively) or doublets in 
the range δ 10.86–11.02 ppm (J1,6 5−6 Hz), while the 
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Scheme 1. Synthesis of 5-aminosulfonyl uracil derivatives 2−9 in pyridine at room temperature 
(yields correspond to analytically pure products). 
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singlets of NH protons of C5 sulfonamido groups are shifted 
upfield and appear in the range δ 9.08–9.77 ppm. The 
multiplet signals within the δ 6.86–8.69 ppm region are 
assigned to the aromatic protons and H-6 protons of uracil 
moiety. 
In vitro Antiproliferative Screening 
5-Aminosulfonyl uracil derivatives 2−9 were tested on in 
vitro cytotoxicity against normal MDCK I cells, solid tumor 
(HeLa, Caco-2, NCI-H358), lymphoma (Raji, HuT78), and 
leukemia (Jurkat, K562) cell lines. 5-Fluorouracil (5-FU) was 
used as the positive control. All cells were treated by 
investigated compounds in the 10–4–10–7 mol dm–3 range of 
concentrations (with exception of compound 9, which was 
found insoluble at c = 10–4 mol dm–3) using 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay method. 
 Compounds 2−9 showed modest to negligible 
effects on normal (MDCK I) and solid tumor (HeLa, Caco-2, 
and NCI-H358) cells growth (Supporting Information 
Figures S18-S20, Table S1). For example, at the highest 
applied concentration (10–4 mol dm–3) 2,4,6-triisopropyl-
benzenesulfonamide 3, 4-nitrobenzenesulfonamide 5, and 
2-nitrobenzenesulfonamide 6 derivatives showed low 
(10−20 %) growth inhibition activities against MDCK I cell 
lines (Figure 3; Supporting Information Figure S17). Similarly, 
at 10–4 mol dm–3, compounds 2–4 and compound 9 at c = 
10–5−10–6 mol dm–3, caused the reduction (10−20 %) of 
HeLa cells growth (Supporting Information Figure S18); 
compounds 2 and 9 inhibited growth of CaCo-2 cells 
(Supporting Information Figure S19), while compounds 2–
4, 7, and 9 inhibited growth of NCI-H358 cells (Supporting 
Information Figure S20). The lower concentrations of the 
tested compounds 2−8 (c = 10–5−10–7 mol dm–3) had no 
significant influence on the growth of normal and solid 
tumor cells. 
 However, 5-aminosulfonyl uracil derivatives 2−9 were 
more efficient to lymphoma and leukemia cells compared 
to normal and solid tumor (HeLa, Caco-2, NCI-H358) cell 
lines. Compounds 2−8 showed statistically significant 
influence at the highest concentrations (c = 10–4 mol dm–3) 
on the lymphoma (Raji, HuT78) and leukemia (Jurkat, K562) 
cells (Supporting Information Figures S21–S24).  
 The strongest cytotoxic effect was found for 4-acet-
amidobenzenesulfonamide 4 (71.4 % of growth inhibition). 
Also, strong inhibition effects were observed for tosyl-
sulfonamide 2 (64.8 %) and naphthalene-1-sulfonamide 8 
(56.4 %). Other tested compounds showed only modest 
cytotoxic activity on Raji cells (less than 50 % of inhibition). At 
the lower range of concentrations (10–5−10–7 mol dm–3), 
tested compounds exhibited insignificant effects on Raji cell 
lines growth (Supporting Information Figure S21).  
 In comparison to effects on Raji cells, tested 
compounds demonstrated similar results on HuT78 cells 
(Supporting Information Figure S22). Compounds 2−8 
applied at 10–4 mol dm–3 showed strong activity on HuT78 
cells growth. The most potent effect showed 2-nitro 
benzenesulfonamide 6, with 57 % of cell inhibition. Our 
results indicate that only dabsyl-sulfonamide 9 applied at 
concentration 10–5 mol dm–3 caused inhibition of 21 % of 
human T cell lymphoma. Other compounds applied at 
105−10–7 mol dm–3 concentration ranges have no or only 
weak inhibition effect on the tested cell lines.  
 Applied at the highest concentration range, 
compounds 2−6, and 8 inhibited more than 50 % of the 
growth of Jurkat cells (Figure 4, Supporting Information 
Figure S23). Also, 2,4,6-triisopropylbenzenesulfonamide 3 
applied at c =10–5 mol dm–3, caused a 20 % reduction of 
Jurkat cell growth. Interestingly, most of the tested 
compounds applied at lower concentration range (10–6 and 
10–7 mol dm–3) showed even a slight increase of Jurkat cell 
growth. 
 The most interesting results were obtained for the 
K562 cell lines (Figure 5; Supporting Information Figure 
S24). Compounds 2, 3, 7, 8, and 9 showed significant 
growth inhibitory effects in all applied range of con-
centrations. The most pronounced cytotoxic effect was 
observed for 2,4,6-triisopropylbenzenesulfonamide 3 at 
10–4 mol dm–3 (39.2 %). Also, at lower concentrations, 
significant inhibitory effects was observed for 3 (65.6 %,  
c = 105 mol dm–3) and dabsyl-sulfonamide 9 (63−74 %,  
c = 105−10–7 mol dm–3). 4-Nitrobenzenesulfonamide 5 and 
2-nitrobenzenesulfonamide 6 failed to show any K562 
cytotoxicity at the applied concentration range of 10–5− 
10–7 mol dm–3. 
 
Figure 3. Cytotoxic effects of 5-aminosulfonyl uracil 
derivatives 2−9 on normal Madin-Darby canine kidney 
(MDCK I) cell lines growth after 72 h of incubation in the final 
concentration range (◼ 10–4, ◼ 10–5, ◼ 10–6 and ◼ 10–7  
mol dm–3). Cytotoxicity was analyzed using the MTT survival 
assay. Data are presented as the mean value ± SD of three 
independent experiments done in triplicates. 
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 IC50 and SI values were also calculated for 5-amino-
sulfonyl uracil derivatives 2−9 for all the cell lines and 
compared to those calculated for 5-FU, the common 
chemotherapy drug (Supporting Information Table S1). IC50 
values calculated for solid tumor (HeLa, Caco-2, NCI-H358) 
cell lines along with the normal cell line, MDCK I, were more 
than100×10–6 mol dm–3. Although compounds 2−8 showed 
a statistically significant influence at the highest applied 
concentrations (c = 10–4 mol dm–3) on lymphoma (Raji, 
HuT78) and leukemia (Jurkat, K562) cells (Supporting 
Information Figures S21–S24) calculated selectivity index 
(SI) indicates that the new compounds generally lack 
anticancer specificities (Table 1). An exception is Jurkat cells 
where greater efficacy against tumor cells compared to 
normal cells is observed. The SI value calculated for 5-FU 
for Jurkat cell lines was low (0.7), indicating the superiority 
of compounds 2-6 and 8 (SI 1.2−2.1) compared to 5-FU. 
CONCLUSIONS 
A small library of 5-aminosulfonyl uracil derivatives 2−9 
with different aromatic substituents at C5-NH-SO2- of uracil 
moiety was efficiently synthesized (yields 58−98 %). The 
products were prepared using equimolar amounts of 5-
aminouracil 1 and selected aromatic sulfonyl chloride in 
pyridine at room temperature.  
 The prepared compounds were tested for the 
antiproliferative activity on normal MDCK I cells and tumor 
HeLa, Caco-2, NCI-H358, Raji, HuT78, Jurkat, K562 cell lines. 
All of the newly synthesized compounds 2−9 showed only 
modest growth inhibition activity on normal (MDCK I) and 
solid tumor (HeLa, Caco-2, NCI-H358) cells. However, they 
were found more active on lymphoma (Raji, HuT78) and 
leukemia (Jurkat, K562) cells, showing statistically 
significant growth inhibition at the highest concentrations 
 
Figure 4. Cytotoxic effects of 5-aminosulfonyl uracil 
derivatives 2−9 on Jurkat cells growth after 72 h of 
incubation in the final concentration range (◼ 10–4, ◼ 10–5, 
◼ 10–6 and ◼ 10–7 mol dm–3). Cytotoxicity was analyzed 
using the MTT survival assay. Data are presented as the 
mean value ± SD of three independent experiments done in 
triplicates. 
 
Figure 5. Cytotoxic effects of 5-aminosulfonyl uracil 
derivatives 2−9 on K562 cells growth after 72 h of 
incubation in the final concentration range (◼ 10–4, ◼ 10–5, 
◼ 10–6 and ◼ 10–7 mol dm–3). Cytotoxicity was analyzed 
using the MTT survival assay. Data are presented as the 
mean value ± SD of three independent experiments done in 
triplicates. 
Table 1. Inhibitory effects of 5-aminosulfonyl uracil derivatives 2−9 and 5-FU on the growth of leukemia, lymphoma, and normal cells. 
 IC50 (1 × 10–6 mol dm–3) 
 Normal cells Leukemia and lymphoma cells 
Comp. MDCK I Raji SI HuT78 SI K562 SI Jurkat SI 
2 >100 70.4 ± 0.6 1.4 >100  >100  80.6 ± 4.2 1.2 
3 >100 >100  >100  78.4 ± 28.2 1.3 47.9 ± 4.3 2.1 
4 >100 57.2 ± 13.6 1.7 >100  >100  79.9 ± 12.1 1.3 
5 >100 >100  >100  >100  78.1 ± 8.2 1.3 
6 >100 >100  86.0 ± 1.4 1.2 >100  63.3 ± 17.4 1.6 
7 >100 >100  >100  >100  >100  
8 >100 87.1 ± 4.5 1.1 >100  >100  77.5 ± 8.7 1.3 
9 >100 >100  >100  >100  >100  
5FU 55.0± 8.7 >100  >100  9.8±0.5 5.6 76.3± 11.4 0.7 
IC50: the concentration that causes 50 % growth inhibition. Data represent the mean IC50 (1 × 10–6 mol dm–3) value of three independent experiments ± SD. 
SI = IC50 for normal cell line MDCK I / IC50 for respective tumor cell line. 
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(20−60 % growth inhibition at c =10–4 mol dm–3). It should 
be noted that due to efficient synthetic protocol the 
sulfonyl group substituents of 5-aminosulfonyl uracil 
derivatives II could be easily varied providing the 
opportunity for diverse structural variations which may 
result with significant improvement of biological 
properties. 
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